Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Dec;49(12):1541-1545.
doi: 10.1111/imj.14654.

RET-rearranged non-small-cell lung cancer and therapeutic implications

Zoe Loh  1 , Paul Mitchell  1 , Thomas John  1   2   3 , Surein Arulananda  1   2   3
Affiliations
Case Reports

RET-rearranged non-small-cell lung cancer and therapeutic implications

Zoe Loh et al. Intern Med J. 2019 Dec.

Abstract

First-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto-oncogene, which occur in 1-2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non-small-cell lung cancer in the era of precision medicine.

Keywords: RET rearrangement; genomic profiling; non-small-cell lung cancer; tyrosine kinase inhibitor; vandetanib.

PubMed Disclaimer

References

    1. Australian Institute of Health and Welfare. Cancer compendium: information and trends by cancer type, lung cancer. [cited 2018 Oct 1]. Available from URL: https://www.aihw.gov.au/reports/cancer/cancer-compendium-information-tre...
    1. Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J 2016; 48: 889-902.
    1. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377: 829-38.
    1. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2017; 378: 113-25.
    1. Drosten M, Pützer BM. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006; 3: 564.

Publication types